Low-Dose Naltrexone Titration for Fibromyalgia
For a fibromyalgia patient currently on 1 mg LDN nightly with a pain score of 5.6, increase the dose to 2.5 mg at bedtime and continue titrating by 1.5 mg every 2 weeks until reaching the target dose of 4.5 mg nightly.
Recommended Titration Schedule
The evidence-based approach for LDN titration in fibromyalgia follows a specific protocol 1:
- Current dose: 1 mg at bedtime
- Next step: Increase to 2.5 mg at bedtime (an increase of 1.5 mg)
- Subsequent increases: Add 1.5 mg every 2 weeks (bi-weekly)
- Target dose: 4.5 mg at bedtime
This means your patient's schedule should be:
- Weeks 1-2: 2.5 mg nightly
- Weeks 3-4: 4.0 mg nightly
- Week 5 onward: 4.5 mg nightly (target maintenance dose)
Evidence Supporting This Approach
The guideline recommendation from Ophthalmology specifically states that LDN should be started at 1.5 mg at bedtime with gradual bi-weekly increases of 1.5 mg to a final maximum dose of 4.5 mg taken at bedtime 1. Since your patient is already at 1 mg, they are close to the recommended starting point and should follow the standard titration protocol.
Research supports 4.5 mg as the optimal dose. A dose-response study found ED50 (effective dose in 50% of patients) at 3.88 mg and ED95 at 5.40 mg, confirming that 4.5 mg is an appropriate target 2. Multiple RCTs in fibromyalgia used 4.5 mg successfully, showing significant pain reduction (28.8% reduction vs 18.0% with placebo, p=0.016) and improved quality of life 3, 4.
Important Caveats
Monitor for side effects during titration: The most common adverse effects include vivid dreams, headache, and transient insomnia 1, 3. These are typically mild and resolve within days. If vivid dreams become problematic, consider taking the dose earlier in the evening (6-7 PM) rather than at bedtime.
Individual response varies significantly: While the evidence shows benefit at the group level, approximately 32% of patients achieve clinically meaningful response (defined as significant pain reduction plus improvement in either fatigue or sleep) 3. Some patients may need doses outside the standard range—the dose-response study used 0.75-6 mg 2—but start with the evidence-based protocol first.
Allow adequate trial duration: After reaching 4.5 mg, maintain this dose for at least 8 weeks before determining efficacy 4. Pain reduction may not be immediate, and some patients show progressive improvement over the treatment period.
Context Within Fibromyalgia Management
While LDN shows promise as an off-label treatment, recognize that established first-line therapies for fibromyalgia include antidepressants (duloxetine, milnacipran, amitriptyline) and anticonvulsants (pregabalin, gabapentin) with Level Ib, Grade A evidence 5, 6, 5. LDN is not mentioned in major fibromyalgia guidelines (EULAR 2008,2017; CDC 2022), reflecting its status as an emerging off-label option with more limited but growing evidence 5, 6, 7.
If inadequate response at 4.5 mg after 8-12 weeks: Consider either adding a first-line agent (duloxetine 60 mg daily or pregabalin 150-225 mg twice daily) or switching to these established therapies 6, 7. The recent meta-analysis showed LDN reduced pain (SMD -0.61) but with high heterogeneity, and some larger trials found no superiority over placebo 8, 9, 10, suggesting not all patients respond.
Practical note: LDN at these low doses requires compounding pharmacy preparation, as standard naltrexone tablets are 50 mg 11. Ensure your patient has access to a reliable compounding pharmacy that can prepare accurate low-dose formulations.